“Fifth Annual National Leadership Summit on 340B Highlights Program’s Impact on Patients”
Stakeholders from across the healthcare industry joined AIR340B for its fifth annual National Leadership Summit on 340B in May 2018. The discussion focused on proposed legislative and regulatory changes, as well as other steps policymakers could take to improve the program. Representative Larry Bucshon (R-IN-08), architect of the bipartisan 340B PAUSE Act, and Adam Fein, CEO of the Drug Channels Institute, delivered remarks. Attendees also heard from patient advocacy groups, legal experts, and congressional staff on the unintended adverse effects of the program and the timeline for proposed fixes.
“Fourth Annual Summit Brings Together Program Stakeholders to Discuss Impact of 340B Program”
At the fourth annual summit, program stakeholders including academic researchers, providers, and legal experts came together to discuss the trajectory of the 340B program and the impact of the program’s growth on patients throughout the country. The more-than 80 attendees heard from Senator Bill Cassidy as well as Congressman Chris Collins about increasing concern among legislators about the unsustainability of the program and the need for legislative solutions to ensure the program continues to support vulnerable or uninsured patients.
“340B Stakeholders Examine the Safety Net at Third Annual Summit”
More than 70 stakeholders, including grantees, patient advocates, clinical specialists, academic organizations, hospitals and the biopharmaceutical industry, convened in Washington in June, 2016 for the third National Leadership Summit on 340B. The third-annual summit, organized by the Alliance for Integrity and Reform of 340B (AIR 340B), focused on a critical aspect of the 340B program: the changing face of the safety net and how to best support those uninsured or vulnerable patients in need of the 340B program. Speakers included Congressional staff, policy thought leaders, representatives from community health centers, and a Member of Congress.
“As Congressional Interest in 340B Grows, 50+ House Offices Attend Briefing; Rep. Collins Raises Concerns Over 340B’s Failures to Serve Vulnerable Patients”
Panelists were joined by Congressman Chris Collins (R-NY), who in his introductory remarks spoke about his personal experience with the program as a former top hospital administrator. Rep. Collins called into question whether the program’s growth over the last two decades has truly led to more patients seeing the benefits.
“AIR 340B Hosts Hill Briefing on Program Sustainability & Implications for Patients”
Dozens of Hill offices came together to hear presentations from industry experts about the origins of the 340B program and the challenges that must be addressed to ensure the program’s sustainability.
“Broad Stakeholder Group Examines 340B Sustainability at Second National Summit”
At the second-annual summit, leaders from the federal government and a broad spectrum of stakeholder groups, including representatives of federal 340B grantees, patient and specialty organizations, industry and academic institutions and a disproportionate share hospital (DSH), continued an open dialogue about the benefits and shortfalls of the 340B Drug Pricing Program.
“Members Press for Specific Program Changes as Congress Holds First Hearing on 340B in Nearly a Decade”
For the first time in nearly a decade, the House Energy and Commerce Subcommittee on Health held a hearing to examine the 340B Drug Pricing Program. Members of Congress from both sides of the aisle raised questions about the program’s accountability and transparency and encouraged HRSA to address the administrative shortcomings of the program through regulatory action.